Trial
NCT07092410
Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
SRH Wald-Klinikum Gera GmbH
Collaborators
Pierre Fabre Pharma GmbH
Condition
Melanoma BRAF V600E/K Mutated
Intervention
Encorafenib & Binimetinib Treatment
Why stopped
The study was terminated early due to insufficient patient recruitment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-21